Research at PKDF
Since the Foundation’s establishment in 1982, it has invested almost $50 million in more than 1,300 research, clinical and scientific grants, awards, fellowships and scientific meetings. The Foundation’s financial commitment over the years has seen results on a local, national and even global level, including initiating funding for young investigators from around the world; supporting innovative research ideas; and providing seed funding to researchers to allow researchers world-wide to apply for larger National Institutes of Health (NIH) grants.
PKDF’s Grants and Fellowships Programs
The principal goal of our research grant program is the development of clinical interventions for the treatment of PKD. Explore available funding opportunities.
The Research Grant and Fellowship Programs will fund critical research to increase understanding of the genetic and pathological processes involved in PKD
Resources for PKD clinicians and researchers
Up to Date information about treating PKD
We partnered with UptoDate to provide medical professionals education on PKD.
PKD Outcomes Consortium
Created to facilitate clinical trial development by establishing a clear regulatory pathway to evaluate the effectiveness of potential treatments
Members of the PKD community have signed up for updates on new clinical research. Do you have a study open for enrollment?
Data resources in PKD research
By encouraging utilization of existing datasets, the Foundation hopes to bring new perspectives. Learn more here.
Explore the latest in polycystic kidney disease publications and articles from our grantees, collaborators, and other PKD experts.
See past winners or nominate your peers for the Lillian Jean Kaplan International Prize for Advancement in the Understanding of PKD
For patients who want to get involved in research
Sign up for a study or clinical trial in PKD
From observational studies to clinical trials, patients can help researchers unlock the secrets of PKD and find a treatment by participating in a study.
The first in the U.S., the secure and patient-powered ADPKD Registry will advance research and help us #endPKD.
Become a stakeholder reviewer
Join our panel and provide a patient/caregiver perspective in PKDF’s annual research grant review process.
PKD treatment pipeline
Learn about the treatments for PKD currently being developed in the United States.
Getting a nephrectomy? Donate your PKD kidney to research
Our PKD tissue donation program provides patients with an avenue to contribute to the advancement of our understanding of PKD.
Spotlight on PKDF grantees and publications
PKDF funds researchers and clinician scientists across the world who are dedicated to finding answers to help us better understand polycystic kidney disease. Here are some highlights of their work.
Harini Ramalingam, Ph.D.
University of Texas Southwestern Medical Center
“ADPKD is the most common genetic cause of renal failure. Current treatment options are limited. miRNAs have emerged as novel pathogenic regulators of ADPKD progression. Anti-miR-based drugs represent a new therapeutic modality to treat ADPKD patients.” – Harini Ramalingam, Ph.D.
Read one of Dr. Ramalingam’s recent publications:
Whitney Besse, M.D.
“Clinical genetic testing is not without challenges, but with careful analysis and collaboration, it has the potential to accelerate progress in our understanding of the mechanistic basis of kidney disease and development of targets for treatments that could alter the landscape of both inherited and acquired kidney disease.” – Whitney Besse, M.D.
Read some of Dr. Besse’s recent publications:
Owen Woodward, Ph.D.
University of Maryland Baltimore
“My lab is working on growing our understanding of how kidney cysts start to grow. We grow kidney tubules in gel so they can form their normal 3D shape. Then because of their special engineering, we can cut out the PKD DNA just by adding a chemical and watching the tubes turn into cysts. We can stop this process at different time points to ask, “What has changed?” Which proteins have become more abundant, which are less, which genes are turned on, which are turned off? By knowing the very first things that start the cyst growing, maybe we can target this process and stop new cysts from forming. Fewer cysts mean lower disease burden.“ – Owen Woodward, Ph.D.
Read one of Dr. Woodward’s recent publications:
Last updated April 2021